Medline resumed with a Buy at Citi
Citi resumed coverage of Medline (MDLN) with a Buy rating and $60 price target following a period of suspension. The company’s Q4 report came in well ahead of expectations on broad-based strength, the analyst tells investors in a research note. Citi believes Medline has a “compelling set-up” into fiscal 2026 as a “safety trade.”
Read More on MDLN:
- Medline price target raised to $53 from $50 at JPMorgan
- Medline price target raised to $60 from $55 at Tigress Financial
- Medline 75M share Secondary priced at $41.00
- Medline announces launch of secondary offering of Class A common stock
- Medline files to sell 75M shares of Class A common stock for holders
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OSC: 25% of Canadians now own crypto assets, usage outpaces speculation
Cash Cat Reclaims Robinhood Chain Crown After Q2 Earnings Call
July 29 ETF Flows Favor Bitcoin, Solana and XRP
Eleanor Terrett Identifies Who Exactly Is Opposing the BRCA Framework
Crypto prices
More
